TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT06176781

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
Study: NCT05424796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostasis and cavity disinfection with KTP laser
Description: Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product E with 1.5% nicotine
Description: P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product E with 1.5% nicotine
Description: P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product E with 1.5% nicotine
Description: P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT06288607

Intervention type: DEVICE
Intervention: High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)
Description: Patients are randomly assigned to be treated with high-intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China) on one side, and the other side is not treated.Before treatment, patients are allowed to sign an informed consent form. Before and after treatment, the L\*a\*b\* values of the lesion area and the area around the lesion are detected using 3nh HIGH-QUALITY COLORMETER colorimeter (Konica-Minolta Company, Japan), and photos of the patient's treatment area and dermatoscope observation results are taken. Before treatment, a 2-3mm thick medical condensation gel is evenly applied on the face. During the process, D4.5+D3.0 transducer are used.
Study: NCT05770427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make the Connection® Online Program
Description: Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by parents and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching parents to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment.
Study: NCT05465382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline Lavage
Description: Three rounds of 10cc of sterile 0.9% normal saline will be injected into the injured ankle joint and withdrawn from the joint using an anteromedial 16-gauge needle attached to a 10cc syringe.
Study: NCT05616754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
Description: The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
Description: The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
Description: This strain was made from the NCP-RBD receptor binding region of the spike glycoprotein of novel coronavirus expressed in recombinant CHO cells, which was purified and added with aluminum hydroxide adjuvant
Study: NCT06189534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
Study: NCT06301204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: tranexamic acid administration 250mg or 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: tranexamic acid administration 250mg or 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: onyl ıv saline (NaCl 0.09%)
Study: NCT05946421

Intervention type: DEVICE
Intervention: exhaled breath analysis
Description: non invasive technology to measure components of exhaled breath

Intervention type: DEVICE
Intervention: exhaled breath analysis
Description: non invasive technology to measure components of exhaled breath
Study: NCT05655819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: 5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
Study: NCT04966520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)
Description: Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be \~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days.
Study: NCT05901285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAX014
Description: Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
Study: NCT05391750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06510205

Intervention type: DEVICE
Intervention: Mentor Breast implants
Description: Mentor breast implants are circular or waterdrop-shaped devices with shells made of successive cross-linked layers of silicone elastomer. The shell is filled with Mentor's proprietary formulation of silicone gel.~Mentor breast implants are available in smooth and textured shells, both supplied in sterile form.
Study: NCT06423677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Posterior Superior Intercostal Plane Block
Description: The Serratus Posterior Superior Intercostal Plane Block will be performed under ultrasound guidance. During the block, a linear ultrasound probe will be placed parallel to the spine of the scapula on the surgical side and then slid medially. The block needle will be advanced under ultrasound guidance over the 3rd rib. After the needle touches the rib, it will be withdrawn by 1mm, and the block site will be confirmed by injecting sterile 0.9% NaCl. Subsequently, patients will be administered 50mg of bupivacaine and 100mg of lidocaine in a controlled manner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient controlled analgesia
Description: intravenous patient-controlled analgesia (PCA) with 4mg/ml Tramadol HCl in 100ml NaCl. There will be no basal infusion, with bolus doses of 20mg and a lockout period of 20 minutes, and a total dose limitation of 200mg over 4 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient controlled analgesia
Description: intravenous patient-controlled analgesia (PCA) with 4mg/ml Tramadol HCl in 100ml NaCl. There will be no basal infusion, with bolus doses of 20mg and a lockout period of 20 minutes, and a total dose limitation of 200mg over 4 hours
Study: NCT06364059

Intervention type: PROCEDURE
Intervention: Decompressive craniectomy with evacuation of subdural hematoma
Description: Adult patients who underwent decompressive craniectomy with evacuation of subdural hematoma.
Study: NCT06069726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: One dose of atezolizumab will be given prior to resection.
Study: NCT05540678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FibreGum
Description: To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
Study: NCT05681884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
Study: NCT06373146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product E with 1.5% nicotine
Description: P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product E with 1.5% nicotine
Description: P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT06373146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab-Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab-Placebo
Description: Administered SC
Study: NCT06780709

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wellness Program and Behavioral Counseling
Description: The comprehensive wellness evaluation will include initial assessments by dietician, social worker, physical therapist, nurse practitioner, and a behavioral neuropsychologist. Each provider will conduct an initial evaluation at baseline to identify areas of need and patient driven goals, as well as follow-up evaluations to evaluate implementation of changes and barriers to change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Program and Behavioral Counseling
Description: The comprehensive wellness evaluation will include initial assessments by dietician, social worker, physical therapist, nurse practitioner, and a behavioral neuropsychologist. Each provider will conduct an initial evaluation at baseline to identify areas of need and patient driven goals, as well as follow-up evaluations to evaluate implementation of changes and barriers to change.
Study: NCT06781489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Description: Oral gabapentin capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arginine
Description: Oral ibuprofen arginine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arginine
Description: Oral ibuprofen arginine tablets
Study: NCT06790901

Intervention type: PROCEDURE
Intervention: LUNG ULTRASOUND
Description: Determination of atelectsis By Lung Ultrasound Score

Intervention type: PROCEDURE
Intervention: LUNG ULTRASOUND
Description: Determination of atelectsis By Lung Ultrasound Score

Intervention type: PROCEDURE
Intervention: LUNG ULTRASOUND
Description: Determination of atelectsis By Lung Ultrasound Score
Study: NCT06792344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T cells
Description: Intravenous injection the targeting CD19 CAR T cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T cells
Description: CD19-targeting CAR-T cells
Study: NCT06785844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (Botox )
Description: Botulinum Toxin injection
Study: NCT06791044

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DELTIUS
Description: A treatment plan will be implemented, as applicable, consisting of 50,000 I.U of vitamin D weekly for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DELTIUS
Description: A treatment plan will be implemented, as applicable, consisting of 50,000 I.U of vitamin D weekly for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DELTIUS
Description: A treatment plan will be implemented, as applicable, consisting of 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks (totaling 8 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DELTIUS
Description: A treatment plan will be implemented, as applicable, consisting of 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks (totaling 8 weeks)
Study: NCT05723198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06792162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carilizumab and Apatinib
Description: After every 2 cycles of meparticipants. Apatinib was discontinued for one cycle and an additional course of Carilizumab was administered in preparation for surgery. The time between the last dose and surgery was 3-6 weeks, with a maximum of 6 weeks. Both surgical and non-surgical participants will continue to receive treatment with the original regimen of Carilizumab combined with Apatinib after surgery until disease progression, recurrence, or death, for a maximum of 2 years.
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product E with 1.5% nicotine
Description: P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT06790927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The doctor prescribes medication for patients and follow-up every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks treatment, amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets after one month, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.
Study: NCT06792357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vagal Active Tone Application Procedure
Description: First section; A video will be created that includes pictures and visuals describing the vagus nerve, explaining its benefits, and providing information about its effects and usage during the birth process.~Second section; Deep breathing and focus exercises;~Feather Breath:~Candle Breath: The pregnant woman inhaled and exhaled as if she was trying to blow out a candle.~Relaxation Breath: Deep breath Third section; Body relaxation exercises; Fourth section; Facial muscle relaxation exercises; Fifth section; Neck and larynx muscle relaxation exercises;
Study: NCT06791096

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-assisted auscultation
Description: The study begins with non-blinded staff collecting medical histories and primary care doctors conducting face-to-face auscultations and assessments. These doctors will then use AI-assisted stethoscopes to collect heart sounds following a set protocol, uploading the recordings to a cloud platform. The AI model analyzes the data in real-time and provides an immediate diagnostic result, which is relayed back to the primary care physicians. Based on this, they will make a secondary assessment. All participants will also undergo echocardiography.
Study: NCT06417827

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SP patients-actors
Description: SP Actors employed by MesserMSR, the Israeli Center for Medical Simulation, trained to simulate symptoms of psychiatric illnesses.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients
Description: Patients (n=150) examined in the psychiatric division and emergency room (ER) of Sheba Medical center. Or people who applied following an advertisement on social networks.
Study: NCT06791096

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Independent auscultation
Description: It includes medical history collection by non-blinded independent personnel, face-to-face auscultation and evaluations conducted by primary care doctors. All participants will undergo echocardiography.
Study: NCT04932122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal wrist ganglion alone (DWG)
Description: Patients assigned to this arm will undergo dorsal wrist ganglion cyst excision alone.
Study: NCT06133205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catgut Embedding at acupoints
Description: Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Catgut Embedding at acupoints
Description: Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
Study: NCT06417827

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Control group- patients
Description: Control group (n=50) Patients who came to the ER at the hospital due to physical complaints, and no psychiatric history.